Use of combination of satins as antagonists of SPARC in stomach cancer: an in silico study

Abstract

SPARC is a protein found in gastric cell line. It has a dual role of tumor suppression and tumor progression. Over expression of SPARC in gastric cell line can lead to Stomach / Gastric cancer which is one of the leading cause of death worldwide. Over the past few years, drug repurposing and other in silico computational techniques have been considered as an ideal approach to discover newer therapeutic alternatives to treat cancer like disease. The application of drug repurposing and molecular docking can play a major role to identify options in the treatment of Stomach / Gastric cancer. Over secretion of SPARC is responsible for Stomach / Gastric cancer. Antagonists of SPARC can be considered as a treatment of choice. In this study, various combination drugs were investigated by applying several in silico approaches. Different combinations of statin drugs were made and among them combination of (Atorvastatin + Pitavastatin) proved to have better antagonistic activity towards the targeted protein SPARC. The combination of (Atorvastatin + Pitavastatin) showed properties that make it a viable option to be considered in Stomach / Gastric cancer therapy with a binding affinity of -9.2 kcal/ mol.